ZhongAn Partners With Orig3n

Orig3n, a Boston-based biotech company announced a new partnership with online insurer ZhongAn, to bring health tech solutions to Chinese consumers.

ZhongAn, which raised $1.5 billion during its IPO in late 2017, will now introduce new healthcare solutions including a suite of DNA tests, backed by Orig3n’s genetic testing applications. Orig3n, which raised a total of $50m, helps people understand the links between their genes and how their minds and bodies work. For example, the company provides a DNA test to help people understand how their genes may affect their fitness potential.

“We are very excited to have ZhongAn as a strategic partner in China. With our strong knowledge base and IP and ZhongAn’s brand awareness and extensive reach with consumers, we are confident that together we will make a significant impact in the PRC.” – CEO of Orig3n, Robin Y. Smith.

“We had been looking to complement ZhongAn’s product suite with health tech solutions to meet evolving consumer demands and identified Orig3n as the ideal partner due to its technology and industry-leading mobile platform. We look forward to partnering with Orig3n to provide innovative new products for our customers and the broader China market.” – President of Life Sciences at ZhongAn, Liu Haijiao.

As part of the partnership, the two companies will also establish a new laboratory in Shanghai to focus on the application and innovation of healthcare technologies, and to provide Chinese consumers with personalized healthcare solutions.